Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 10
2.1 Therapy Area Introduction 10
2.2 Symptoms 10
2.2.1 Pneumonia 10
2.2.2 RSV 10
2.2.3 PAH 11
2.2.4 Tuberculosis 11
2.3 Diagnosis 11
2.3.1 Pneumonia 11
2.3.2 RSV 11
2.3.3 PAH 12
2.3.4 Tuberculosis 12
2.4 Etiology and Pathophysiology 12
2.4.1 Pneumonia 14
2.4.2 RSV 14
2.4.3 PAH 15
2.4.4 Tuberculosis 16
2.5 Epidemiology 17
2.5.1 Pneumonia 17
2.5.2 RSV 18
2.5.3 PAH 18
2.5.4 Tuberculosis 19
2.6 Comorbidities and Complications 20
2.6.1 Pneumonia 20
2.6.2 RSV 20
2.6.3 PAH 20
2.6.4 Tuberculosis 21
2.7 Prognosis 21
2.7.1 Pneumonia 21
2.7.2 RSV 21
2.7.3 PAH 21
2.7.4 Tuberculosis 21
2.8 Treatment 22
2.8.1 Antibiotics 22
2.8.2 Antiviral Drugs 24
2.8.3 Vaccines 25
2.8.4 Antihypertensive drugs 26
2.8.5 Anticoagulants 26
2.8.6 Non-Pharmacological Treatments 27
3 Marketed Products 28
3.1 Overview 28
3.2 Prevnar 13 – Pfizer 30
3.3 Synflorix – GlaxoSmithKline 31
3.4 Uptravi – Actelion 32
3.5 Opsumit – Actelion 33
3.6 Eliquis – Bristol-Myers Squibb and Pfizer 34
3.7 Xarelto – Bayer 36
3.8 Synagis – Medimmune 37
3.9 Ventolin – GlaxoSmithKline 38
3.10 Infanrix and Boostrix – GlaxoSmithKline 39
4 Pipeline Landscape Assessment 42
4.1 Overview 42
4.2 Pipeline Development Landscape 42
4.3 Molecular Targets in the Pipeline 45
4.4 Clinical Trials 48
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target 48
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target 52
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target 56
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target 59
4.4.5 Conclusion 62
4.5 Assessment of Key Pipeline Products 63
4.5.1 Solithera – Cempra 63
4.5.2 Carbavance (meropenem and vaborbactam) –The Medicines Company 64
4.5.3 Respiratory Syncytial Virus Vaccine – Novavax 65
4.5.4 Conclusion 66
5 Multi-scenario Market Forecast to 2022 67
5.1 Overall Market Size 67
5.2 Generic Penetration 69
5.3 Revenue Forecast by Molecular Target and Drug Category 70
5.3.1 Vaccines 70
5.3.2 G-Protein Coupled Receptors 71
5.3.3 Enzyme Targets 72
5.3.4 Bacterial and Viral Targets 72
5.4 Revenue and Market Share Analysis by Company 73
5.4.1 Pfizer – Prevnar Dominates Respiratory Complications Revenue 77
5.4.2 Actelion – Rapid Growth of PAH Therapies to Create a Strong Market Position 78
5.4.3 GSK – Vast Product Portfolio Will Help Maintain a Strong Market Position 80
5.4.4 Bayer – Despite Limited Portfolio, Xarelto Performance Sufficient to Establish Strong Market Position 81
5.4.5 Bristol-Myers Squibb – Growing Eliquis Revenue to Improve Respiratory Complications Market Position 81
5.4.6 Novavax – Approval of RSV Vaccine Will Help Establish Market Presence 82
5.4.7 United Therapeutics – Variant Treprostinil Formulation to Form Cornerstone of Market Presence 83
6 Company Analysis and Positioning 85
6.1 Company Landscape 86
6.2 Marketed and Pipeline Portfolio Analysis 86
7 Strategic Consolidations 89
7.1 Licensing Deals 89
7.1.1 Deals by Region, Value and Year 89
7.1.2 Deals by Stage of Development and Value 90
7.1.3 Deals by Molecule Type, Mechanism of Action and Value 91
7.1.4 Licensing Deals Valued Above $100m 93
7.2 Co-development Deals 95
7.2.1 Deals by Region, Value and Year 95
7.2.2 Deals by Stage of Development and Value 96
7.2.3 Deals by Molecule Type and Value 97
7.2.4 Co-development Deals Valued Above $100m 99
8 Appendix 101
8.1 Bibliography 101
8.2 All Pipeline Drugs by Phase of Development 106
8.2.1 Discovery 106
8.2.2 Preclinical 123
8.2.3 IND/CTA-filed 165
8.2.4 Phase I 166
8.2.5 Phase II 176
8.2.6 Phase III 186
8.2.7 Pre-registration 192
8.2.8 Unknown 193
8.3 Abbreviations 194
8.4 Methodology 195
8.4.1 Coverage 195
8.4.2 Secondary Research 196
8.4.3 Market Size and Revenue Forecasts 196
8.4.4 Pipeline Analysis 196
8.4.5 Competitive Landscape 197
8.5 Contact Us 197
8.6 Disclaimer 197